

From: ratna.lingamaneni/cambridge/biogen;nsf;ratna.lingamaneni@biogenidec.com;smtp
Sent: Tue Dec 27 2005 15:31:11 EST
To: [redacted];alfred.sandrock/cambridge/biogen@ [redacted]
 [redacted];cara.lansden/cambridge/biogen [redacted]
 [redacted];tammy.sarnelli/cambridge/biogen@ [redacted]
 [redacted];gilmore.o'neill/cambridge/biogen@biogenidec; [redacted]
CC: [redacted];ratna.lingamaneni/cambridge/biogen@biogenidec;
MoodStamp: Normal
Subject: Re: BG12 MS IND - Cross functional review - Comments due by TOMORROW

Dear all,

Please note that your comments on BG12 MS IND Module 2 are due tomorrow, Dec 28th.
 Thank you
 -Ratna

Ratna Lingamaneni/Cambridge/Biogen
 12/19/2005 03:03 PM
 Message Size: 2617.8 KB

To
 [redacted]
 [redacted] Cara
 Lansden/Cambridge/Biogen@BiogenIdec.
 [redacted]
 Tammy Sarnelli/Cambridge/Biogen@BiogenIdec
 [redacted] Gilmore
 O'Neill/Cambridge/Biogen@BiogenIdec
 [redacted]
 Subject
 BG12 MS IND - Cross functional review - Comments due by Dec 28

<http://rel-web/Relativity.Distributed/Download.aspx?ArtifactID=1168211&GUID=f0626...> 11/12/2015

Dear all,

Please note that BG12 IND for MS indication has been sent to you for review via BRASS workflow. The document is also attached below for those who do not have access to BRASS. Your comments are due by Dec 28th.

Please let me know if you have any questions or need any referenced study reports for your review.



Module 2.pdf

Thank you
-Ratna

Ratna Lingamaneni, PhD
Manager, Regulatory Affairs
Tel: (617) 679-2231
Fax: (617) 679-3170